BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 16428439)

  • 21. Expression and differential signaling of heregulins in pancreatic cancer cells.
    Kolb A; Kleeff J; Arnold N; Giese NA; Giese T; Korc M; Friess H
    Int J Cancer; 2007 Feb; 120(3):514-23. PubMed ID: 17096356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction or suppression of expression of cytochrome C oxidase subunit II by heregulin beta 1 in human mammary epithelial cells is dependent on the levels of ErbB2 expression.
    Sun Y; Lin H; Zhu Y; Ma C; Ye J; Luo J
    J Cell Physiol; 2002 Aug; 192(2):225-33. PubMed ID: 12115729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A high-affinity ErbB4Fc fusion protein is a potent antagonist of heregulin-mediated receptor activation.
    Koziolek EJ; Donoghue JF; Bentley JD; Lovrecz G; Dolezal O; Ward CW; Rothacker J; Nice EC; Burgess AW; Hafner M; Johns TG; Adams TE
    Growth Factors; 2012 Oct; 30(5):310-9. PubMed ID: 22856597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells.
    Fiddes RJ; Janes PW; Sivertsen SP; Sutherland RL; Musgrove EA; Daly RJ
    Oncogene; 1998 May; 16(21):2803-13. PubMed ID: 9652748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG; Ethier SP
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells.
    Noguchi H; Sakamoto C; Wada K; Akamatsu T; Uchida T; Tatsuguchi A; Matsui H; Fukui H; Fujimori T; Kasuga M
    Gastroenterology; 1999 Nov; 117(5):1119-27. PubMed ID: 10535875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.
    Schaefer G; Fitzpatrick VD; Sliwkowski MX
    Oncogene; 1997 Sep; 15(12):1385-94. PubMed ID: 9333014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer.
    Yonezawa M; Wada K; Tatsuguchi A; Akamatsu T; Gudis K; Seo T; Mitsui K; Nagata K; Tanaka S; Fujimori S; Sakamoto C
    Digestion; 2009; 80(4):215-25. PubMed ID: 19797898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration.
    Xiong S; Grijalva R; Zhang L; Nguyen NT; Pisters PW; Pollock RE; Yu D
    Cancer Res; 2001 Feb; 61(4):1727-32. PubMed ID: 11245489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
    Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC
    Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
    Ram TG; Schelling ME; Hosick HL
    Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
    Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
    Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling.
    Hatakeyama M; Kimura S; Naka T; Kawasaki T; Yumoto N; Ichikawa M; Kim JH; Saito K; Saeki M; Shirouzu M; Yokoyama S; Konagaya A
    Biochem J; 2003 Jul; 373(Pt 2):451-63. PubMed ID: 12691603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.
    Weingaertner IR; Koutnik S; Ammer H
    PLoS One; 2013; 8(1):e53510. PubMed ID: 23308242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The neuregulin-I/ErbB signaling system in development and disease.
    Britsch S
    Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.
    Puricelli L; Proietti CJ; Labriola L; Salatino M; Balañá ME; Aguirre Ghiso J; Lupu R; Pignataro OP; Charreau EH; Bal de Kier Joffé E; Elizalde PV
    Int J Cancer; 2002 Aug; 100(6):642-53. PubMed ID: 12209601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
    Kim S; Han J; Shin I; Kil WH; Lee JE; Nam SJ
    Exp Mol Med; 2012 Aug; 44(8):473-82. PubMed ID: 22627808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
    Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
    Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.